Agilent Names Simon May to Lead Diagnostics and Genomics Group

Rhea-AI Summary

Agilent Technologies, Inc. (NYSE: A) has appointed Simon May as the president of the Diagnostics and Genomics Group (DGG). May, previously from Bio-Rad Laboratories, brings a wealth of experience to Agilent. He will be joining the company on May 6th. The CEO-elect, Padraig McDonnell, expressed excitement about May's technical expertise, experience, and focus on strategy. May's background includes roles at Bio-Rad and Thermo Fisher Scientific, with academic credentials from the University of Liverpool.

Positive

• None.

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies, Inc. (NYSE: A) today announced Simon May has been named president of the company’s Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science Group at Bio-Rad Laboratories, will join Agilent on May 6.

“We are excited to welcome Simon May to the Agilent team,” said Padraig McDonnell, COO and CEO-elect. “Simon’s deep technical knowledge, his broad range of experience, and his career-long focus on strategy, continuous improvement and operational excellence are critical additions to our DGG organization as we capitalize on the opportunities that lie in front of us in helping our customers bring great science to life.”

Prior to his role with the Life Science Group, Simon served in other positions at Bio-Rad, including senior vice president and general manager of the Digital Biology Group, and as senior vice president of Global Commercial Operations. Before joining Bio-Rad in 2014, May held positions at Thermo Fisher Scientific for 10 years as well as MWG Biotech. He began his career in laboratory roles before moving into sales, product-management, and business-leadership positions.

May earned his bachelor’s degree and his doctorate in genetics/molecular biology from England’s University of Liverpool, where he later spent two years as a postdoctoral research fellow.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers’ most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240429621286/en/

Media Contact:

Tom Beermann

+1 408-386-5892

tom.beermann@agilent.com

Investor Contact:

Parmeet Ahuja

+1 408-345-8948

parmeet_ahuja@agilent.com

Source: Agilent Technologies Inc.

FAQ

Who is the new president of Agilent's Diagnostics and Genomics Group?

Simon May has been named the new president of Agilent's Diagnostics and Genomics Group.

When will Simon May start at Agilent?

Simon May will join Agilent on May 6th.

What is Simon May's background?

Simon May previously worked at Bio-Rad Laboratories and Thermo Fisher Scientific. He holds a bachelor's degree and a doctorate in genetics/molecular biology from the University of Liverpool.